REMEGEN2025年欧洲肿瘤内科学会(ESMO)年会将于当地时间10月17日至21日在德国柏林召开,荣昌生物(688331.SH/09995.HK)11项原创研究成果成功入选。其中多项临床研究数据为首次在国际公布,充分彰显中国创新药在全球肿瘤精准治疗领域的突破实力与影响力。本次大会上,荣昌生物的多项重磅研究成果将集中亮相。其中,维迪西妥单抗联合治疗一线尿路上皮癌的RC48-C016Ⅲ期临床研究...
Source LinkREMEGEN2025年欧洲肿瘤内科学会(ESMO)年会将于当地时间10月17日至21日在德国柏林召开,荣昌生物(688331.SH/09995.HK)11项原创研究成果成功入选。其中多项临床研究数据为首次在国际公布,充分彰显中国创新药在全球肿瘤精准治疗领域的突破实力与影响力。本次大会上,荣昌生物的多项重磅研究成果将集中亮相。其中,维迪西妥单抗联合治疗一线尿路上皮癌的RC48-C016Ⅲ期临床研究...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.